Top

Published in:

01-05-2015 | Hypertension and Obesity (E Reisin, Section Editor)

Cardiovascular and Renal Effects of Weight Reduction in Obesity and the Metabolic Syndrome

Authors: Jordana B. Cohen, Debbie L. Cohen

Published in: Current Hypertension Reports | Issue 5/2015

Abstract

Obesity is a critical public health issue worldwide. Patients with obesity have markedly increased morbidity and mortality compared to the general population. The increased health risks of obesity in part are due to its close association with each of the other components of the metabolic syndrome, including hypertension, dyslipidemia, and insulin resistance. Accordingly, obese individuals are at particularly increased risk of cardiovascular disease and chronic kidney disease. Modest weight loss results in improvements in serum cholesterol levels, blood pressure, and glycemic profiles. Lifestyle interventions for weight loss have long been the mainstay of treatment in obesity. However, the existing literature demonstrates limited weight loss sustainability and inconsistent cardiovascular and renal benefits using these modalities. In addition to improvements in intermediate risk factors, surgical interventions provide a more lasting impact on long-term cardiovascular and renal outcomes, though carry higher short-term risks due to perioperative complications.

WHO Consultation on Obesity. Obesity: preventing and managing the global epidemic. Geneva, Switzerland: World Health Organization. WHO Technical Report Series. 2000;894:9.

Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–7. doi:https://doi.org/10.1001/jama.288.14.1723.PubMed

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. NCHS data brief, no 82. Hyattsville, MD: National Center for Health Statistics. 2012. https://doi.org/www.cdc.gov/nchs/data/databriefs/db82.pdf.

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. doi:https://doi.org/10.1001/jama.2014.732.PubMedPubMedCentral

Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond). 2013;37(6):889–91. doi:https://doi.org/10.1038/ijo.2012.159.

Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. PharmacoEconomics. 2014. doi:https://doi.org/10.1007/s40273-014-0230-2.PubMedCentral

Shihab HM, Meoni LA, Chu AY, Wang NY, Ford DE, Liang KY, et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012;126(25):2983–9. doi:https://doi.org/10.1161/CIRCULATIONAHA.112.117333.PubMedPubMedCentral

Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88. doi:https://doi.org/10.1186/1471-2458-9-88.PubMedPubMedCentral

Berthoux F, Mariat C, Maillard N. Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol Dial Transplant. 2013;28 suppl 4:iv160–6. doi:https://doi.org/10.1093/ndt/gft286.PubMed

10.

System. URD. USRDS 2014 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2014. https://doi.org/www.usrds.org/2014/download/V2_Ch_01_ESRD_Incidence_Prevalence_14.pdf.

11.

Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–8.PubMed

12.

Burton JO, Gray LJ, Webb DR, Davies MJ, Khunti K, Crasto W, et al. Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrol Dial Transplant. 2012;27(5):1860–6. doi:https://doi.org/10.1093/ndt/gfr574.PubMed

13.

Thethi T, Kamiyama M, Kobori H. The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep. 2012;14(2):160–9.PubMedPubMedCentral

14.

DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014;10(6):364–76. doi:https://doi.org/10.1038/nrendo.2014.44.PubMedPubMedCentral

15.

Amann K, Benz K. Structural renal changes in obesity and diabetes. Semin Nephrol. 2013;33(1):23–33. doi:https://doi.org/10.1016/j.semnephrol.2012.12.003.PubMed

16.•

Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8:CD003641. doi:https://doi.org/10.1002/14651858.CD003641.pub4. In this recent Cochrane Review of RCT’s evaluating one to two year outcomes following bariatric surgery, the authors concluded that bariatric surgery results in greater, more sustained reduction in body weight and obesity-associated comorbidities compared to non-surgical interventions. The authors also noted that adverse events associated with bariatric surgery and re-operation rates are poorly reported in the literature.

17.

Shaw K, Gennat H, O’Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006;4, CD003817. doi:https://doi.org/10.1002/14651858.CD003817.pub3.

18.

Mastellos N, Gunn LH, Felix LM, Car J, Majeed A. Transtheoretical model stages of change for dietary and physical exercise modification in weight loss management for overweight and obese adults. Cochrane Database Syst Rev. 2014;2, CD008066. doi:https://doi.org/10.1002/14651858.CD008066.pub3.

19.

Lin JS, O’Connor EA, Evans CV, Senger CA, Rowland MG, Groom HC. Behavioral counseling to promote a healthy lifestyle for cardiovascular disease prevention in persons with cardiovascular risk factors: an updated systematic evidence review for the U.S. Preventive Services Task Force. US Preventive Services Task Force Evidence Synthesis. 2014;13-05179-EF-1.

20.

Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6. doi:https://doi.org/10.2337/dc10-2415.PubMedPubMedCentral

21.••

Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54. doi:https://doi.org/10.1056/NEJMoa1212914. This large, multi-center RCT randomized patients with type 2 diabetes to lifestyle interventions (including calorie-restricted diet and increased physical activity) versus diabetes support and education, with plans to follow patients up to 13.5 years. The study was discontinued early on the basis of futility because of a failure to detect a difference in cardiovascular events between the treatment and control groups after a median follow up of 9.6 years.

22.

Walker M, Wannamethee G, Whincup PH, Shaper AG. Weight change and risk of heart attack in middle-aged British men. Int J Epidemiol. 1995;24(4):694–703.PubMed

23.

Nilsson PM, Nilsson JA, Hedblad B, Berglund G, Lindgarde F. The enigma of increased non-cancer mortality after weight loss in healthy men who are overweight or obese. J Intern Med. 2002;252(1):70–8.PubMed

24.

Pamuk ER, Williamson DF, Serdula MK, Madans J, Byers TE. Weight loss and subsequent death in a cohort of U.S. adults. Ann Intern Med. 1993;119(7 Pt 2):744–8.PubMed

25.

Pack QR, Rodriguez-Escudero JP, Thomas RJ, Ades PA, West CP, Somers VK, et al. The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis. Mayo Clin Proc. 2014;89(10):1368–77. doi:https://doi.org/10.1016/j.mayocp.2014.04.033.PubMedPubMedCentral

26.

Wieland LS, Falzon L, Sciamanna CN, Trudeau KJ, Brodney S, Schwartz JE, et al. Interactive computer-based interventions for weight loss or weight maintenance in overweight or obese people. Cochrane Database Syst Rev. 2012;8, CD007675. doi:https://doi.org/10.1002/14651858.CD007675.pub2.PubMedCentral

27.

Uusitupa M, Peltonen M, Lindstrom J, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, et al. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study—secondary analysis of the randomized trial. PLoS One. 2009;4(5):e5656. doi:https://doi.org/10.1371/journal.pone.0005656.PubMedPubMedCentral

28.

Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783–9. doi:https://doi.org/10.1016/S0140-6736(08)60766-7.PubMed

29.

Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg. 2014;149(3):275–87. doi:https://doi.org/10.1001/jamasurg.2013.3654.PubMedPubMedCentral

30.

Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93. doi:https://doi.org/10.1056/NEJMoa035622.PubMed

31.

Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond). 2008;32 Suppl 7:S93–7. doi:https://doi.org/10.1038/ijo.2008.244.

32.•

Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13. doi:https://doi.org/10.1056/NEJMoa1401329. This single center RCT of obese type 2 diabetics randomized 150 patients to intensive medical therapy versus bariatric surgery (Roux-en-Y gastric bypass or gastric sleeve). At three years of follow up, patients who underwent surgical intervention had significantly higher rates of remission of type 2 diabetes compared to those randomized to medical therapy alone. Those surgical patients who remained on antiglycemic medications were on less aggressive regimens compared to the medical intervention group. Patients who underwent bariatric surgery had much more dramatic weight loss and improved quality of life compared to medical therapy alone.PubMedPubMedCentral

33.

Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–85. doi:https://doi.org/10.1056/NEJMoa1200111.PubMed

34.

Halperin F, Ding SA, Simonson DC, Panosian J, Goebel-Fabbri A, Wewalka M, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014;149(7):716–26. doi:https://doi.org/10.1001/jamasurg.2014.514.PubMedPubMedCentral

35.••

Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. doi:https://doi.org/10.1001/jama.2014.5988. This important publication from the Swedish Obese Subjects prospective matched cohort study demonstrated diminished diabetes remission rates fifteen years following bariatric surgery, though remission rates remained significantly higher than patients who did not undrego surgical intervention. Patients who underwent bariatric surgery benefited from significant reductions in long-term microvascular and macrovascular diabetic complications compared to usual care.PubMed

36.

Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98(24):1763–77. doi:https://doi.org/10.1136/heartjnl-2012-301778.PubMed

37.

Kwok CS, Pradhan A, Khan MA, Anderson SG, Keavney BD, Myint PK, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol. 2014;173(1):20–8. doi:https://doi.org/10.1016/j.ijcard.2014.02.026.PubMed

38.

Scott JD, Johnson BL, Blackhurst DW, Bour ES. Does bariatric surgery reduce the risk of major cardiovascular events? A retrospective cohort study of morbidly obese surgical patients. Surg Obes Relat Dis. 2013;9(1):32–9. doi:https://doi.org/10.1016/j.soard.2011.09.002.PubMed

39.

Johnson BL, Blackhurst DW, Latham BB, Cull DL, Bour ES, Oliver TL, et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg. 2013;216(4):545–56. doi:https://doi.org/10.1016/j.jamcollsurg.2012.12.019. discussion 56–8.PubMed

40.••

Sjostrom L, Peltonen M, Jacobson P, Sjostrom CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65. doi:https://doi.org/10.1001/jama.2011.1914. Another important publication from the Swedish Obese Subjects prospective matched cohort study, this analysis exhibited significant 15-year decrease in cardiovascular mortality, myocardial infarction, and stroke in patients who underwent bariatric surgery compared to usual care.PubMed

41.

Zhuo JL, Li XC. New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides. 2011;32(7):1551–65. doi:https://doi.org/10.1016/j.peptides.2011.05.012.PubMedPubMedCentral

42.

Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41(2):319–27. doi:https://doi.org/10.1053/ajkd.2003.50039.PubMed

43.

Praga M, Hernandez E, Andres A, Leon M, Ruilope LM, Rodicio JL. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron. 1995;70(1):35–41.PubMed

44.

Straznicky NE, Grima MT, Lambert EA, Eikelis N, Dawood T, Lambert GW, et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens. 2011;29(3):553–64. doi:https://doi.org/10.1097/HJH.0b013e3283418875.PubMed

45.

Van Huffel L, Tomson CR, Ruige J, Nistor I, Van Biesen W, Bolignano D. Dietary restriction and exercise for diabetic patients with chronic kidney disease: a systematic review. PLoS One. 2014;9(11):e113667. doi:https://doi.org/10.1371/journal.pone.0113667.PubMedPubMedCentral

46.

MacLaughlin HL, Cook SA, Kariyawasam D, Roseke M, van Niekerk M, Macdougall IC. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. Am J Kidney Dis. 2010;55(1):69–76. doi:https://doi.org/10.1053/j.ajkd.2009.09.011.PubMed

47.

Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant. 2013;28 Suppl 4:iv82–98. doi:https://doi.org/10.1093/ndt/gft302.PubMed

48.

Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol. 2003;14(6):1480–6.PubMed

49.

Eriksen BO, Melsom T, Mathisen UD, Jenssen TG, Solbu MD, Toft I. GFR normalized to total body water allows comparisons across genders and body sizes. J Am Soc Nephrol. 2011;22(8):1517–25. doi:https://doi.org/10.1681/ASN.2010121321.PubMedPubMedCentral

50.

Shen WW, Chen HM, Chen H, Xu F, Li LS, Liu ZH. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol. 2010;5(8):1401–9. doi:https://doi.org/10.2215/CJN.01370210.PubMedPubMedCentral

51.

Georgaki-Angelaki H, Stergiou N, Manolaki N, Nakopoulou L, Syriopoulou VP, Roma-Giannikou E. Histological deterioration of obesity-related glomerulopathy despite the loss of proteinuria with weight reduction. Pediatr Nephrol. 2010;25(8):1573–4. doi:https://doi.org/10.1007/s00467-010-1475-4.PubMed

52.

Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1565–74. doi:https://doi.org/10.2215/CJN.02250409.PubMedPubMedCentral

53.

Hou CC, Shyu RS, Lee WJ, Ser KH, Lee YC, Chen SC. Improved renal function 12 months after bariatric surgery. Surg Obes Relat Dis. 2013;9(2):202–6. doi:https://doi.org/10.1016/j.soard.2012.10.005.PubMed

54.

Reid TJ, Saeed S, McCoy S, Osewa AA, Persaud A, Ahmed L. The effect of bariatric surgery on renal function. Surg Obes Relat Dis. 2014;10(5):808–13. doi:https://doi.org/10.1016/j.soard.2014.02.048.PubMed

55.

Miras AD, Chuah LL, Lascaratos G, Faruq S, Mohite AA, Shah PR, et al. Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care. 2012;35(12):e81. doi:https://doi.org/10.2337/dc11-2353.PubMedPubMedCentral

56.

Amor A, Jimenez A, Moize V, Ibarzabal A, Flores L, Lacy AM, et al. Weight loss independently predicts urinary albumin excretion normalization in morbidly obese type 2 diabetic patients undergoing bariatric surgery. Surg Endosc. 2013;27(6):2046–51. doi:https://doi.org/10.1007/s00464-012-2708-3.PubMed

57.

Saliba J, Kasim NR, Tamboli RA, Isbell JM, Marks P, Feurer ID, et al. Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. Surgery. 2010;147(2):282–7. doi:https://doi.org/10.1016/j.surg.2009.09.017.PubMed

58.

Fenske WK, Dubb S, Bueter M, Seyfried F, Patel K, Tam FW, et al. Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. 2013;9(4):559–68. doi:https://doi.org/10.1016/j.soard.2012.03.009.PubMed

59.

Navaneethan SD, Malin SK, Arrigain S, Kashyap SR, Kirwan JP, Schauer PR. Bariatric surgery, kidney function, insulin resistance, and adipokines in patients with decreased GFR: a cohort study. Am J Kidney Dis. 2014. doi:https://doi.org/10.1053/j.ajkd.2014.09.018.PubMed

60.

Iaconelli A, Panunzi S, De Gaetano A, Manco M, Guidone C, Leccesi L, et al. Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. Diabetes Care. 2011;34(3):561–7. doi:https://doi.org/10.2337/dc10-1761.PubMedPubMedCentral

61.

Alexander JW, Goodman HR, Hawver LR, Cardi MA. Improvement and stabilization of chronic kidney disease after gastric bypass. Surg Obes Relat Dis. 2009;5(2):237–41. doi:https://doi.org/10.1016/j.soard.2008.08.016.PubMed

62.

Fowler SM, Kon V, Ma L, Richards WO, Fogo AB, Hunley TE. Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. Pediatr Nephrol. 2009;24(4):851–5. doi:https://doi.org/10.1007/s00467-008-1024-6.PubMed

63.

Huan Y, Tomaszewski JE, Cohen DL. Resolution of nephrotic syndrome after successful bariatric surgery in patient with biopsy-proven FSGS. Clin Nephrol. 2009;71(1):69–73.PubMed

64.•

Turgeon NA, Perez S, Mondestin M, Davis SS, Lin E, Tata S, et al. The impact of renal function on outcomes of bariatric surgery. J Am Soc Nephrol. 2012;23(5):885–94. doi:https://doi.org/10.1681/ASN.2011050476. This retrospective database study evaluated surgical complications in patients with underlying renal disease. Increased severity of CKD directly predicted complication rates associated with bariatric surgery; this relationship persisted after adjusting for underlying hypertension and diabetes.PubMed

65.

Weingarten TN, Gurrieri C, McCaffrey JM, Ricter SJ, Hilgeman ML, Schroeder DR, et al. Acute kidney injury following bariatric surgery. Obes Surg. 2013;23(1):64–70. doi:https://doi.org/10.1007/s11695-012-0766-1.PubMed

Title: Cardiovascular and Renal Effects of Weight Reduction in Obesity and the Metabolic Syndrome
Authors: Jordana B. Cohen
Debbie L. Cohen
Publication date: 01-05-2015
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 5/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-015-0544-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cardiovascular and Renal Effects of Weight Reduction in Obesity and the Metabolic Syndrome

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Assessment of Right Ventricular Function in Pulmonary Hypertension

LCZ696: The Next Step in Improving RAS Inhibition?

Control of Energy Balance by the Brain Renin-Angiotensin System

Hypothalamic Signaling Mechanisms in Hypertension

Hypertension in Pregnancy: Natural History and Treatment Options

Capillary Rarefaction as an Index for the Microvascular Assessment of Hypertensive Patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page